Trial Search Results
Seal, Stopping Atopic Dermatitis and Allergy Study
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 10 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Stanford is currently not accepting patients for this trial.
Collaborator: National Jewish Health
- Combination Product: Tri-lipid skin barrier cream (Epiceram)
- Combination Product: Fluticasone propionate Cream 0.05%
Phase 1/Phase 2
1. Participants who develop early onset atopic dermatitis up to 10 weeks of age.
2. Stated willingness to comply with all study procedures and availability for the
duration of the study
3. In good general health as evidenced by medical history
1. Infants that are small for gestational age
2. Infants with a chronic disease requiring therapy (e.g. heart disease, diabetes,
serious neurological defects),
3. parents or guardians unwilling to sign consent.
Ages Eligible for Study
N/A - 10 Weeks
Genders Eligible for Study